U.S. License Holder:
UCB Inc.
Date of License:
June-26-2023
Last Update:
Oct-23-2024
FDA-Approved Indications
RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.